Trials / Withdrawn
WithdrawnNCT06535828
AIM4 AI and Mechanistic Modeling in Molecular Medicine
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess for potential pitfalls and to assess the feasibility of the approach of analysis of new tumor biopsies for selection of standard of care treatment selection in patients with metastatic hormone receptor positive breast cancer who have developed disease progression on 1st line endocrine therapy combined with a CDK4/6 inhibitor.
Detailed description
Primary Objective To assess the feasibility and utility of tumor evaluation to aid in selection of standard of care therapy for patients with hormone receptor positive (HR+) /HER2- advanced/metastatic breast cancer. Secondary Objectives * Accrual Rate (AR) * Clinical Benefit Rate (CBR) * To compare progression free survival (PFS) based on concordance with recommended treatment * Duration of Response (DoR) * Therapy Acceptance Rate (TAR)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | AI and mechanic modeling | The data collected from research tests on your blood and tumor samples will be used to develop an AI model for treatment selection. |
Timeline
- Start date
- 2024-11-30
- Primary completion
- 2025-01-15
- Completion
- 2025-01-15
- First posted
- 2024-08-02
- Last updated
- 2025-01-17
Source: ClinicalTrials.gov record NCT06535828. Inclusion in this directory is not an endorsement.